206 related articles for article (PubMed ID: 9272116)
1. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Herman EH; Zhang J; Hasinoff BB; Chadwick DP; Clark JR; Ferrans VJ
Cancer Chemother Pharmacol; 1997; 40(5):400-8. PubMed ID: 9272116
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
3. dl-N,N'-dicarboxamidomethyl-N,N'-dicarboxymethyl-1,2-diaminopropane (ICRF-198) and d-1,2-bis(3,5-dioxopiperazine-1-yl)propane (ICRF-187) inhibition of Fe3+ reduction, lipid peroxidation, and CaATPase inactivation in heart microsomes exposed to adriamycin.
Vile GF; Winterbourn CC
Cancer Res; 1990 Apr; 50(8):2307-10. PubMed ID: 2156615
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals.
Malisza KL; Hasinoff BB
Arch Biochem Biophys; 1995 Feb; 316(2):680-8. PubMed ID: 7864623
[TBL] [Abstract][Full Text] [Related]
5. The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin.
Hasinoff BB
Agents Actions; 1989 Mar; 26(3-4):378-85. PubMed ID: 2544086
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187.
Zhang J; Clark JR; Herman EH; Ferrans VJ
J Mol Cell Cardiol; 1996 Sep; 28(9):1931-43. PubMed ID: 8899552
[TBL] [Abstract][Full Text] [Related]
7. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
Schroeder PE; Hasinoff BB
Cancer Chemother Pharmacol; 2002 Dec; 50(6):509-13. PubMed ID: 12451479
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat.
Schroeder PE; Hasinoff BB
Drug Metab Dispos; 2005 Sep; 33(9):1367-72. PubMed ID: 15980099
[TBL] [Abstract][Full Text] [Related]
9. The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction.
Thomas C; Vile GF; Winterbourn CC
Biochem Pharmacol; 1993 May; 45(10):1967-72. PubMed ID: 8390256
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
Herman EH; Zhang J; Ferrans VJ
Cancer Chemother Pharmacol; 1994; 35(2):93-100. PubMed ID: 7987999
[TBL] [Abstract][Full Text] [Related]
11. Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin.
Vaidyanathan S; Boroujerdi M
Cancer Chemother Pharmacol; 2000; 46(2):93-100. PubMed ID: 10972478
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats.
Herman EH; el-Hage A; Ferrans VJ
Toxicol Appl Pharmacol; 1988 Jan; 92(1):42-53. PubMed ID: 3124293
[TBL] [Abstract][Full Text] [Related]
13. Effects of ICRF-186 [(L)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats.
Zhang J; Herman EH; Ferrans VJ
Toxicology; 1994 Sep; 92(1-3):179-92. PubMed ID: 7940559
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
Herman EH; Ferrans VJ; Myers CE; Van Vleet JF
Cancer Res; 1985 Jan; 45(1):276-81. PubMed ID: 3917371
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
Alderton PM; Gross J; Green MD
Cancer Res; 1992 Jan; 52(1):194-201. PubMed ID: 1727379
[TBL] [Abstract][Full Text] [Related]
16. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity.
Herman EH; Zhang J; Rifai N; Lipshultz SE; Hasinoff BB; Chadwick DP; Knapton A; Chai J; Ferrans VJ
Cancer Chemother Pharmacol; 2001 Oct; 48(4):297-304. PubMed ID: 11710630
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187.
Zhang J; Herman EH; Ferrans VJ
Am J Pathol; 1993 Jun; 142(6):1916-26. PubMed ID: 8506959
[TBL] [Abstract][Full Text] [Related]
18. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Alderton P; Gross J; Green MD
Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
Herman EH; Zhang J; Chadwick DP; Ferrans VJ
Cancer Chemother Pharmacol; 2000; 45(4):329-34. PubMed ID: 10755322
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of the protective activity of ICRF-187 against alloxan-induced diabetes in mice.
el-Hage A; Herman EH; Yang GC; Crouch RK; Ferrans VJ
Res Commun Chem Pathol Pharmacol; 1986 Jun; 52(3):341-60. PubMed ID: 3090662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
